The Hympavzi European Commission Approval has officially cleared a new path for patients living with hemophilia A and B. Pfizer Inc. announced today that the European Commission (EC) has granted marketing authorization for HYMPAVZI™ (marstacimab), specifically expanding its use to include adults and adolescents aged 12 and older who have developed inhibitors. This decision establishes Hympavzi as a pioneering anti-tissue factor pathway inhibitor (anti-TFPI) therapy in the European Union.
Significance of the Hympavzi European Commission Approval
The Hympavzi European Commission Approval is particularly significant for the “inhibitor” patient population. For many living with hemophilia, the development of inhibitors, antibodies that neutralize traditional factor replacement therapies, represents a major hurdle in managing the disease. Until this approval, treatment options for these patients were often complex and required frequent administration.
By providing a once-weekly subcutaneous injection, this therapy simplifies the treatment regimen significantly. According to Pfizer’s official press release, Hympavzi is now the only once-weekly subcutaneous treatment approved in the EU for both Hemophilia A and B, regardless of inhibitor status.
Clinical Efficacy Behind the Hympavzi European Commission Approval
The clinical foundation for the Hympavzi European Commission Approval rests on the results of the Phase 3 BASIS trial. This study compared the efficacy of Hympavzi against traditional on-demand (OD) therapy and bypassing agents (BPAs).
Key findings from the trial included:
- Simplified Dosing: The transition from frequent intravenous infusions to a once-weekly subcutaneous pen improves patient quality of life.
- Superior Bleed Reduction: A 93% reduction in the mean annualized bleeding rate (ABR) compared to on-demand therapy.
- Long-term Stability: Interim data from open-label extension studies show that bleed reduction is maintained for up to 53 months.
Safety and Administration in the EU
Following the Hympavzi European Commission Approval, healthcare providers can now prescribe this treatment to patients weighing at least 35 kg. While the safety profile is generally favorable, the most common side effects reported include injection site reactions, headaches, and pruritus. It is vital for patients to consult with their hematologists to monitor for potential risks such as thromboembolic events.
This authorization is valid across all 27 EU member states, as well as Iceland, Liechtenstein, and Norway. It represents a 40-year commitment by Pfizer to the hemophilia community, bridging the gap between clinical need and therapeutic innovation.
BASIS Phase 3 Trial Efficacy Summary
| Metric | Hympavzi Prophylaxis | On-Demand (OD) Therapy | Improvement (%) |
| Mean Annualized Bleeding Rate (ABR) | 1.39 | 19.78 | 93% Reduction |
| Median ABR | 0.00 | 16.42 | 100% Reduction |
| Secondary Endpoints | Superior across all | Baseline | Statistically Significant |
Product Specifications and Regulatory Status
| Category | Detail |
| Generic Name | Marstacimab |
| Brand Name | HYMPAVZI™ |
| Mechanism of Action | Anti-Tissue Factor Pathway Inhibitor (anti-TFPI) |
| Route of Administration | Subcutaneous Injection (Pre-filled Pen) |
| Frequency | Once Weekly |
| Indication (EU) | Hemophilia A/B (12+ yrs, ≥35kg) with or without inhibitors |
| Approval Body | European Commission (EC) |
Safety Profile (Common Adverse Events)
| Adverse Event | Frequency (%) | Severity |
| Injection Site Reactions | High | Mild to Moderate |
| Headache | Moderate | Mild |
| Pruritus (Itching) | Moderate | Mild |
| Thrombosis | Low | Serious (Requires Monitoring) |
